Aug 21FDA Drug Approvals in 2023: Insights into Trends and Molecule TypesIn 2023, the U.S. Food and Drug Administration (FDA) approved 55 new drugs, marking a significant year in pharmaceutical advancements....
Jul 31Canurta Therapeutics Secures First US Patent for Novel Bioactive Polyphenol Extraction ProcessJuly 31, 2024 – Toronto, Canada: Canurta Therapeutics is pleased to announce the granting of its first US patent for the company’s...
Jul 17AI: Transforming the Future of NutraceuticalsThe advent of Artificial Intelligence (AI) is revolutionizing the nutraceutical industry, transitioning from traditional development...
May 24Reflecting on the ALS Drug Development Summit in BostonThis week, I had the opportunity to attend the ALS Drug Development Summit in Boston, an event that brought together the brightest minds...
Feb 8Canurta Inc. Unveils Strategic Reorganization & Rebranding: Introducing Canurta Therapeutics and Canurta NaturalsWe are pleased to announce a significant transformation in our corporate structure and brand architecture. The organization will now have...
Mar 13, 2023Canurta Receives Funding from the Government of Canada for Respiratory Disease TherapeuticsThe Company has received $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC...
Mar 9, 2023Interview with The Ontario Centre of InnovationWe're excited to announce that our CEO, Akeem Gardner, was recently interviewed by the Ontario Centre of Innovation (OCI) about the...
Feb 22, 2023Responsible & Resilient: Canurta in your CommunityLetter from our CEO I am writing to you today as the CEO of our company in the biotech and agricultural industries. I understand that...
Sep 28, 2021Canurta’s White Paper: Grounds for Further Investigation into Rare Hemp PolyphenolsGiven the scarcity of Canurta’s novel molecules, they have never been formally assayed in animal or human models. Canurta has committed...